Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. - Wikidata - wikimedia - TriplyDB

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

http://www.wikidata.org/entity/Q34660897

about

Contemporary Treatment of Metastatic Renal Cell Carcinoma Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Pazopanib in the treatment of advanced renal cell carcinoma Sequence of treatment in locally advanced and metastatic renal cell carcinoma Individualising treatment choices in a crowded treatment algorithm Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma Sunitinib in the treatment of metastatic renal cell carcinoma Medical treatment of renal cancer: new horizons Renal cell cancer: overview of the current therapeutic landscape.Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence.Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial.IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Cancer associated fibroblasts in hematological malignancies.Pazopanib-induced alopecia, an underestimated toxicity?Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment.A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale"Oncology Gold Standard™ practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma.First-line treatment options in metastatic renal cell cancer.New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma Pazopanib: a review of its use in the management of advanced renal cell carcinoma.Kidney cancer in 2014: Key advances promise progress for kidney cancer patients.Sequencing systemic therapies for metastatic kidney cancer.Pazopanib for the treatment of renal cell carcinoma.Kidney cancer and 2014: is innovation really over?Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives.Emerging tyrosine kinase inhibitors for the treatment of renal cancer.Application of the American Society of Clinical Oncology frameworks to compare tyrosine kinase inhibitors used in first line treatment of metastatic renal cell carcinoma: Had we solved the mystery?

P2860

Q26740594-961C1F12-D11A-41A2-83C2-2F76F5AFB8DB Q26766240-C67131F3-BB14-4A7D-8F66-978949448FEB Q26770413-54C6CF4E-7749-4F23-A57D-AF52C6A44DEC Q26773653-622E9C66-CA5E-46E3-90DA-44B716B9521F Q27023669-C5FC3449-251D-45CE-8810-A55BE8205657 Q28066747-4918543B-4AF4-4AB4-8589-E352B85BAEF5 Q28072057-AD273F35-7310-4683-9687-2687350C3B68 Q28073174-3E5C04E6-C29E-478F-95EF-E5D53EF59F53 Q30248354-786F4355-D143-4432-948A-7A4BAEF3EEF8 Q30250273-6085B155-D7CF-4E88-B8F2-8B992F8CBBFA Q33430940-B6450A09-E809-4808-BB14-B6099EC63D13 Q33686273-3068B5D1-A2B0-4847-AD39-789ED3E88B9C Q33696649-AAF702A2-EE82-4A33-A6A2-71D5EB674EBE Q33821666-C4D54BE6-5D63-4735-AE87-D038EDE645DD Q33922560-95DC9B9A-1446-42FB-B14B-15230193DBA6 Q34105997-CF613E5A-FB70-47AE-B4FD-86A1B06433B1 Q34666150-06E31FE5-E3FD-42C9-9BC8-4BFDA6CC8CEC Q34998569-74F5BEC0-4997-4D4C-9232-5276821BECDF Q35274936-247C6C5F-63F0-49C3-B546-19298F32DF97 Q35550041-64F40092-BB35-42E1-9841-A358B1D66397 Q35591482-E1CDEB09-8469-4317-9C4F-4A04EDAED9F2 Q36067852-0859AC31-2DF9-423F-90AF-CB2BC7E1978D Q36093104-C25D3B50-9F0C-4627-9090-5A7A6406998A Q36384503-6AAE6BF0-1C24-412E-97BA-3D21AD97C6A7 Q36708349-86B9695A-4FD3-46EF-9F2C-026E3823BC4C Q36777194-2A10DBCD-E644-485B-80DB-7BFA29E7239C Q37152908-2D1B1C39-0043-46DC-89C4-7FC740ADF880 Q37218304-1F6F7680-DB2A-4F45-9AF5-4A35069A0CDA Q37532265-D84D3B57-6698-4138-8D2C-7ED7E44A7BA8 Q37560635-60ADDCA8-AF58-41C5-9A78-44BA2DA8D795 Q37620907-379B8361-2E47-4C72-BC5F-37E43FDF6D46 Q37644869-3FAA0151-DFB6-4027-BD95-79F1C566B8AF Q38220728-2BD38E5A-DCD7-4918-98C7-F0FF8355EC4E Q38323542-C3B86EA4-E7DA-410A-976B-C2693FEF3DB2 Q38342983-8B8A59B2-43D0-47A7-AB13-FDE2678EF3C0 Q38400468-67F53D5E-985C-4E50-9CBE-F846F0230E8B Q38465870-B98439F8-2A22-46DF-B31D-265124F7E204 Q38473672-B78FC27D-4274-4021-8CD0-4327A6CC62AE Q38485779-66FCE184-27CD-4B92-AF34-04FCAB32D1C2 Q38598277-885E8FFC-C13C-4DF0-A657-08159E6C0998

P2860

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

http://www.wikidata.org/entity/Q34660897

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Randomized, controlled, double ...... cell carcinoma: PISCES Study.

@ast

Randomized, controlled, double ...... cell carcinoma: PISCES Study.

@en

Randomized, controlled, double ...... cell carcinoma: PISCES Study.

@nl

type

label

Randomized, controlled, double ...... cell carcinoma: PISCES Study.

@ast

Randomized, controlled, double ...... cell carcinoma: PISCES Study.

@en

Randomized, controlled, double ...... cell carcinoma: PISCES Study.

@nl

prefLabel

Randomized, controlled, double ...... cell carcinoma: PISCES Study.

@ast

Randomized, controlled, double ...... cell carcinoma: PISCES Study.

@en

Randomized, controlled, double ...... cell carcinoma: PISCES Study.

@nl

P1433

Q34660897-62D25033-E266-42B4-9B0E-5D9C3667047E

P1476

Q34660897-DC51D90F-3D6F-43E3-AA8E-FE17533C6ED3

P2093

Q34660897-284EAE4C-8851-4835-AFF1-29B53CD6F5FE

Q34660897-31ACF1F3-71D9-48D1-9845-84A92E1533B8

Q34660897-4AC85105-EE79-4A41-A8EE-7F4E4CC29BB6

Q34660897-4C3E9F56-040C-470F-B503-2825C9729D8E

Q34660897-4D96A6E1-93B1-4399-A397-4F43F2C92FFA

Q34660897-52AC9AEC-ED62-44EA-AA35-20E6EEE10E45

Q34660897-69B815D6-F285-43CD-AE4E-BCC8C56E10C2

Q34660897-6C759D17-1AF8-4D11-B2C1-2AEE727FE52C

Q34660897-7AF51D7C-621D-4CFD-B5D3-369C869EB8FD

Q34660897-914E08AC-8DBF-4017-8686-04584A2088CB

P304

Q34660897-760B25E7-2ACF-40A1-AB8C-97538029C4D9

P31

Q34660897-CAADE84C-CA8E-4026-B7E8-7A1AA182CC2D

P356

Q34660897-67DDF40F-EE42-4924-B916-007DBD339941

P407

Q34660897-72184ED8-D975-4AB2-974B-1C096A158D13

P433

Q34660897-7B14B610-80C5-4EF3-9D4B-9F63223153F3

P478

Q34660897-85BE1235-F0E8-42C0-9562-D13E92EFDD46

P50

Q34660897-9D6000B0-BD0F-480C-B822-8C6179DAFCF1

P577

Q34660897-CF86C329-4CDF-4051-8056-EE66088C1C4B

P698

Q34660897-CF839818-C723-4A2E-96B9-6196CA77B82E

P356

JCO.2013.50.8267

P1433

Journal of Clinical Oncology

P1476

Randomized, controlled, double ...... cell carcinoma: PISCES Study.

@en

P2093

Camillo Porta

http://www.w3.org/2001/XMLSchema#string

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

David Cella

http://www.w3.org/2001/XMLSchema#string

Emmanuel Sevin

http://www.w3.org/2001/XMLSchema#string

Faisal Mehmud

http://www.w3.org/2001/XMLSchema#string

Jose Diaz

http://www.w3.org/2001/XMLSchema#string

Jürgen E Gschwend

http://www.w3.org/2001/XMLSchema#string

Omi Parikh

http://www.w3.org/2001/XMLSchema#string

Petri Bono

http://www.w3.org/2001/XMLSchema#string

Robert Hawkins

http://www.w3.org/2001/XMLSchema#string

P304

1412-1418

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.50.8267

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Bernard Escudier

P577

2014-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24687826

http://www.w3.org/2001/XMLSchema#string